Analysis: Diclofenac's heart risks warrant caution

02/14/2013 | TheHeart.org (Montreal) (free registration)

Diclofenac, a nonsteroidal anti-inflammatory drug, was associated with an up to 63% higher risk of cardiovascular events, and should be eliminated from essential-medicines lists, according to a meta-analysis published online in PLoS Medicine. Diclofenac was the most widely used NSAID in 15 countries, and its heart risk was comparable to that of rofecoxib, which was withdrawn from the market due to its cardiovascular toxocicty.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI